{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:41:11Z","timestamp":1788892871844,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ijid.2017.02.020","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T22:48:30Z","timestamp":1488322110000},"page":"18-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia : in vitro effects and clinical efficacy in cancer patients"],"prefix":"10.1016","volume":"58","author":[{"given":"Hideki","family":"Araoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyoshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4596-9643","authenticated-orcid":false,"given":"Akiko","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2017.02.020_bib0005","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1086\/522998","article-title":"Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer","volume":"45","author":"Safdar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2017.02.020_bib0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1473-3099(09)70083-0","article-title":"Stenotrophomonas maltophilia: an emerging opportunist human pathogen","volume":"9","author":"Looney","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2017.02.020_bib0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/CMR.00019-11","article-title":"Stenotrophomonas maltophilia: an emerging global opportunistic pathogen","volume":"25","author":"Brooke","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijid.2017.02.020_bib0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1399-3062.2011.00710.x","article-title":"Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy","volume":"14","author":"Araoka","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijid.2017.02.020_bib0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/bmt.2012.87","article-title":"Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage","volume":"48","author":"Tada","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijid.2017.02.020_bib0030","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3389\/fmicb.2015.00893","article-title":"Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options","volume":"6","author":"Chang","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijid.2017.02.020_bib0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12879-015-0801-7","article-title":"Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations","volume":"15","author":"Cho","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2017.02.020_bib0040","doi-asserted-by":"crossref","first-page":"e0152132","DOI":"10.1371\/journal.pone.0152132","article-title":"Evaluation of Trimethoprim\/Sulfamethoxazole (SXT), Minocycline, Tigecycline Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments","volume":"11","author":"Wei","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2017.02.020_bib0045","series-title":"Performance standards for antimicrobial susceptibility testing; 24th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2014"},{"key":"10.1016\/j.ijid.2017.02.020_bib0050","doi-asserted-by":"crossref","unstructured":"2016 INSTRUCTIONS TO AUTHORS. Antimicrob Agents Chemother. (April) 2016; 1\u201324.","DOI":"10.1016\/S1092-9134(16)30231-3"},{"key":"10.1016\/j.ijid.2017.02.020_bib0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0924-8579(98)00060-0","article-title":"Combination antibiotic therapy versus monotherapy for Gram-negative bacteraemia: a commentary","volume":"11","author":"Chow","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2017.02.020_bib0060","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jmii.2012.08.014","article-title":"Stenotrophomonas maltophilia bloodstream infection: comparison between community-onset and hospital-acquired infections","volume":"47","author":"Chang","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijid.2017.02.020_bib0065","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10096-010-0882-6","article-title":"Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009","volume":"29","author":"Araoka","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2017.02.020_bib0070","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/AAC.01324-13","article-title":"Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.02.020_bib0075","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/AAC.48.1.168-171.2004","article-title":"Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis","volume":"48","author":"San Gabriel","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.02.020_bib0080","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1128\/AAC.39.10.2220","article-title":"In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia","volume":"39","author":"Poulos","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.02.020_bib0085","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3346\/jkms.2013.28.1.62","article-title":"Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates","volume":"28","author":"Chung","year":"2013","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ijid.2017.02.020_bib0090","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10156-010-0068-2","article-title":"Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing","volume":"16","author":"G\u00fclmez","year":"2010","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijid.2017.02.020_bib0095","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s10096-014-2101-3","article-title":"Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia","volume":"33","author":"Betts","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2017.02.020_bib0100","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1179\/1973947814Y.0000000168","article-title":"Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations","volume":"26","author":"Hu","year":"2014","journal-title":"J Chemother"},{"key":"10.1016\/j.ijid.2017.02.020_bib0105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3109\/00365548.2012.732240","article-title":"Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates","volume":"45","author":"Church","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijid.2017.02.020_bib0110","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1128\/AAC.00072-12","article-title":"Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients","volume":"56","author":"Milne","year":"2012","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971217300681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971217300681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T01:52:45Z","timestamp":1568857965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971217300681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":22,"alternative-id":["S1201971217300681"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2017.02.020","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2017.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}